The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathological characteristics and impact on efficacy of three versus six months of adjuvant chemotherapy in early-onset colon cancer: ACHIEVE and ACHIEVE-2 trials.
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Dai Manaka
No Relationships to Disclose
 
Manabu Shiozawa
No Relationships to Disclose
 
Yasuhiro Sakamoto
No Relationships to Disclose
 
Yoshinori Munemoto
No Relationships to Disclose
 
Tetsuya Eto
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Akio Shiomi
No Relationships to Disclose
 
Junichi Hasegawa
No Relationships to Disclose
 
Akitaka Makiyama
Consulting or Advisory Role - Lilly Japan
Speakers' Bureau - Chugai Pharma; Lilly; Takeda
 
Takeharu Yamanaka
Honoraria - Bayer; Boehringer Ingelheim; Chugai Pharma
Consulting or Advisory Role - Gilead Sciences; HUYA Bioscience International; Sysmex
Research Funding - Bayer (Inst); Chugai/Roche (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tsunekazu Mizushima
Consulting or Advisory Role - Takeda
Speakers' Bureau - Abbvie; Daiichi Sankyo; EA Pharma; Janssen; Kyorin; Mitsubishi Tanabe Pharma; Miyarisan pharmaceutical; Sanofi; Sanofi; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Mitsubishi Tanabe Pharma (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Eiji Sunami
No Relationships to Disclose
 
Atsushi Ohtsu
Employment - Celgene (I)
Honoraria - Chugai Pharma; Eisai; Merck Serono; Ono Yakuhin; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb
 
Yoshihiko Maehara
No Relationships to Disclose
 
Masaki Mori
No Relationships to Disclose
 
Takayuki Yoshino
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)